Clinical Trials Logo

Distal Urethral Cancer clinical trials

View clinical trials related to Distal Urethral Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02122172 Terminated - Clinical trials for Stage IV Bladder Cancer

Afatinib in Advanced Refractory Urothelial Cancer

Start date: September 13, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.

NCT ID: NCT01611662 Terminated - Clinical trials for Stage III Bladder Cancer

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Start date: May 29, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to find out what effects, good and/or bad, dose-dense (every 14 days) chemotherapy with gemcitabine (gemcitabine hydrochloride) and cisplatin given before surgery have on patients and their muscle invasive bladder cancer.

NCT ID: NCT00112905 Terminated - Clinical trials for Stage IV Bladder Cancer

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00004856 Terminated - Clinical trials for Stage IV Bladder Cancer

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Start date: July 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.